As GSTM1 and GSTT1 deletions have been associated with alterations in enzyme activity and risk of pulmonary fibrosis, a severe symptom of COVID-19, it was suggested that they might be used as predictors of COVID-19 morbidity and mortality [108]. Here, GSTM1 is linked to COVID-19.